We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Routine Screening Recommended for Sexually Transmitted Disease

By LabMedica International staff writers
Posted on 29 Mar 2011
An improved and more sensitive test should be included in the screening of vaginal swabs for women suspected of having sexually transmitted diseases (STD). More...


A molecular diagnostic assay that uses transcription-mediated amplification (TMA) for the detection of Trichomonas vaginalis augments the laboratory diagnosis of venereal diseases.

Scientists at Rhode Island Hospital (Providence, RI, USA), compared a TMA assay with a direct-specimen, ribonucleic acid (RNA) probe-based diagnostic test designed to differentiate and identify pathogens associated with bacterial vaginosis (Gardnerella vaginalis) and vaginitis (T. vaginalis and Candida species). A total of 781 consecutive specimen pairs, consisting of one vaginal specimen and one cervical or urine specimen, were collected from 766 women from July 2009 to August 2010.

The study revealed that the APTIMA assay (Gen-Probe, San Diego, CA, USA) detected 36% more women infected with T. vaginalis, yielding a sensitivity of 100% and no false positives. The authors noted a high prevalence of trichomoniasis in women in the 36 to 45 year-old age group, who are not normally included in the recommended STD screening criteria. The AFFIRM Vaginitis three pathogens (VPIII) RNA assay, (BD; Franklin Lakes, NJ, USA), which is commonly used in obstetrics and gynecological patients, produced one false positive and 15 false negative results in symptomatic patients.

Trichomoniasis can affect both men and women and the true prevalence and clinical impact is unknown because current methods of detection exhibit poor sensitivity when compared to molecular amplification methods. Kimberle Chapin, MD, lead author of the study, said, "Despite a worldwide prevalence rate likely to be double that of gonorrhea or Chlamydia infections combined, trichomoniasis is not currently a reportable disease in the United States. We also found the disease was most prevalent in women ages 36 to 45 and in women ages 51 to 60. This was definitely surprising and a new finding in these age groups." The study was published in March 2011, in the Journal of Clinical Microbiology.

Related Links:

Rhode Island Hospital
BD
Gen-Probe



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.